Stoke Therapeutics Inc (STOK)
13.90
-0.13
(-0.93%)
USD |
NASDAQ |
May 17, 16:00
13.90
0.00 (0.00%)
After-Hours: 20:00
Stoke Therapeutics Net Income (Quarterly): -26.37M for March 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | -26.37M |
| December 31, 2023 | -26.96M |
| September 30, 2023 | -24.54M |
| June 30, 2023 | -30.65M |
| March 31, 2023 | -22.54M |
| December 31, 2022 | -25.66M |
| September 30, 2022 | -26.11M |
| June 30, 2022 | -24.65M |
| March 31, 2022 | -24.65M |
| December 31, 2021 | -24.45M |
| September 30, 2021 | -22.60M |
| June 30, 2021 | -21.97M |
| March 31, 2021 | -16.79M |
| Date | Value |
|---|---|
| December 31, 2020 | -14.56M |
| September 30, 2020 | -13.68M |
| June 30, 2020 | -12.96M |
| March 31, 2020 | -11.04M |
| December 31, 2019 | -10.16M |
| September 30, 2019 | -8.604M |
| June 30, 2019 | -7.819M |
| March 31, 2019 | -5.742M |
| December 31, 2018 | -4.282M |
| September 30, 2018 | -3.317M |
| June 30, 2018 | -3.01M |
| March 31, 2018 | -1.912M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-30.65M
Minimum
Jun 2023
-7.819M
Maximum
Jun 2019
-19.84M
Average
-22.57M
Median
Net Income (Quarterly) Benchmarks
| NeuBase Therapeutics Inc | -1.821M |
| iBio Inc | -8.211M |
| Actinium Pharmaceuticals Inc | -8.67M |
| Lixte Biotechnology Holdings Inc | -0.9713M |
| Fate Therapeutics Inc | -48.00M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 4.216M |
| Total Expenses (Quarterly) | 32.59M |
| EPS Diluted (Quarterly) | -0.57 |
| Enterprise Value | 545.89M |
| Profit Margin (Quarterly) | -625.6% |
| Earnings Yield | -17.34% |
| Normalized Earnings Yield | -17.34 |